Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00936975
Other study ID # NCI-2010-01292
Secondary ID NCI-2010-01292CD
Status Completed
Phase Phase 2
First received July 9, 2009
Last updated June 22, 2015
Start date September 2009
Est. completion date December 2014

Study information

Verified date December 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well fluorine F 18 sodium fluoride positron emission tomography (PET) works in evaluating response to dasatinib in patients with prostate cancer and bone metastases. Diagnostic procedures, such as fluorine F 18 sodium fluoride PET, may help doctors predict a patient's response to treatment and help plan the best treatment.


Description:

PRIMARY OBJECTIVES:

I. Determine if changes in regional fluoride incorporation, measured by 18F-fluoride PET (SUV and Ki), occur in both castration-resistant prostate cancer bone metastases and normal bone as a response to treatment with dasatinib.

SECONDARY OBJECTIVES:

I. Determine if changes in 18F-fluoride transport (K1), an indicator of blood flow, and therefore, an indirect marker of angiogenesis, occur in both castration-resistant prostate cancer bone metastases and normal bone as a response to treatment with dasatinib.

OUTLINE: This is a multicenter study.

Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. PET parameters (SUV, Ki, and Kl) are also analyzed.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date December 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Must be able to provide a written informed consent

- Men 18 years or older with metastatic castration-resistant prostate cancer enrolling onto the Febbo clinical trial with dasatinib therapy (must meet all inclusion criteria for dasatinib treatment study and comply with requirements of that specific clinical trial)

- Histologic confirmation of original prostate cancer diagnosis

- Presence of at least one convincing bone metastasis as defined by bone scintigraphy, computed tomography (CT) scan (magnetic resonance imaging [MRI] if indicated), or plain X-ray

- Must currently have castrate testosterone levels (< 50 ng/dL) from orchiectomy or maintenance on a luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist

Exclusion Criteria:

- On the nilutamide-only arm (Arm A of the clinical therapeutic trial)

- Note: However, if a patient crosses-over from nilutamide at the time of progression to add dasatinib therapy, he may be eligible for 18F-fluoride PET imaging protocol if he meets all inclusion criteria for this trial

- Any condition that would alter the patient's mental status, prohibiting the basic understanding and/or authorization of informed consent

- A serious underlying medical condition that would otherwise impair the patient's ability to receive treatment and imaging studies

- Expected lifespan of 12 weeks or less

- Extremely poor intravenous access, prohibiting the placement of a peripheral IV line for injection of radiotracer

- Initiation of bisphosphonate therapy less than 4 weeks from the first PET scan

- Radiation treatment to bone less than 4 weeks from first PET scan

- Radiopharmaceutical treatment to bone less than 4 weeks from first PET scan

- Treatment with granulocyte-macrophage colony stimulating factor (GM-CSF) or granulocyte CSF (G-CSF) within 4 weeks prior to first PET scan

- Inability to lie still for the imaging

- Weight > 300 lbs. (due to equipment specifications)

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Radiation:
Fluorine F 18 Sodium Fluoride
Undergo fluorine F 18 sodium fluoride PET scan

Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Duke University Medical Center Durham North Carolina
United States Oregon Health and Science University Portland Oregon
United States University of Washington Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in 18F-fluoride PET (SUV) - Tumor Bone Investigation of changes between baseline and 12 weeks in regional fluoride incorporation as measured by 18F-fluoride PET in tumor bone as measured by SUVmax Baseline and 12 weeks No
Primary Changes in 18F-fluoride PET SUV - Normal Bone Investigation of changes between baseline and 12 weeks in regional fluoride incorporation as measured by 18F-fluoride PET (SUV) in normal bone as measured by SUVmax Baseline and 12 weeks No
Primary Changes in 18F-fluoride Ki - Tumor Bone Investigation of changes between baseline and 12 weeks in regional fluoride incorporation as measured by 18F-fluoride PET (Ki) in tumor bone. Ki represents the net uptake of fluoride to the bone mineral compartment and reflects the level of osteoblastic activity in bone Baseline and 12 weeks No
Primary Changes in 18F-fluoride Ki - Normal Bone Investigation of changes between baseline and 12 weeks in regional fluoride incorporation as measured by 18F-fluoride PET (Ki) in normal bone. Ki represents the net uptake of fluoride to the bone mineral compartment and reflects the level of osteoblastic activity in bone Baseline and 12 weeks No
Secondary Changes in 18F-fluoride Transport (by Patlak Flux) - Tumor Investigation of changes in regional fluoride incorporation as measured by 18F-fluoride transport (Patlak flux) in Tumor. This measurement uses the Patlak method for determining the influx constant. Baseline and 12 weeks No
Secondary Changes in 18F-fluoride Transport (by Patlak Flux) - Normal Investigation of changes in regional fluoride incorporation as measured by 18F-fluoride transport (Patlak flux) in normal bone. Palak flux is an indicator of blood flow and an indirect marker of angiogenesis. Baseline and 12 weeks No
See also
  Status Clinical Trial Phase
Terminated NCT02491411 - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel N/A
Active, not recruiting NCT01685125 - Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 2
Completed NCT00087139 - Ixabepilone in Treating Patients With Metastatic Prostate Cancer Phase 2
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Completed NCT01881867 - CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT01385059 - Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer Phase 2
Terminated NCT01866423 - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT02807805 - Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Phase 2
Completed NCT01468532 - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT01026623 - Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Phase 1/Phase 2
Completed NCT01682941 - Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen N/A
Terminated NCT00536991 - Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer Phase 1/Phase 2
Completed NCT00074022 - GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors Phase 1/Phase 2
Completed NCT03707184 - Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone Phase 2
Withdrawn NCT00003534 - Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer Phase 2
Recruiting NCT04113096 - Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer Early Phase 1
Active, not recruiting NCT03344211 - Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Phase 2
Terminated NCT02985021 - Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies Phase 2
Recruiting NCT02615223 - Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer N/A
Terminated NCT00527124 - Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Phase 2